AGP Picks
View all

Samoa Wellness Report
Provided by AGP

Samoa Wellness Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Samoa Wellness Report.

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

Press releases published on August 24, 2026

Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease
Aug. 24, 2026

Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease

Indeterminate GlobeNewswire
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
Aug. 24, 2026

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

Indeterminate GlobeNewswire
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Aug. 24, 2026

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Indeterminate GlobeNewswire
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
Aug. 24, 2026

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

Indeterminate GlobeNewswire
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
Aug. 24, 2026

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Indeterminate GlobeNewswire
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Aug. 24, 2026

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Indeterminate GlobeNewswire
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Aug. 24, 2026

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

Indeterminate GlobeNewswire
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Aug. 24, 2026

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Indeterminate GlobeNewswire
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Aug. 24, 2026

Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Indeterminate GlobeNewswire
ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE
Aug. 24, 2026

ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE

Indeterminate GlobeNewswire
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
Aug. 24, 2026

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

Indeterminate GlobeNewswire
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Aug. 24, 2026

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

Indeterminate GlobeNewswire
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Aug. 24, 2026

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Indeterminate GlobeNewswire
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
Aug. 24, 2026

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

Indeterminate GlobeNewswire
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Aug. 24, 2026

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Indeterminate GlobeNewswire
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
Aug. 24, 2026

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

Indeterminate GlobeNewswire
Kraig Biocraft Laboratories Boosts Spider Silk Output More Than 30% During the Most Technically Challenging Season of the Year
Aug. 24, 2026

Kraig Biocraft Laboratories Boosts Spider Silk Output More Than 30% During the Most Technically Challenging Season of the Year

Indeterminate GlobeNewswire
Felix Health launches sleep apnea care through new collaboration with MedSleep
Aug. 24, 2026

Felix Health launches sleep apnea care through new collaboration with MedSleep

Indeterminate GlobeNewswire
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
Aug. 24, 2026

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance

Indeterminate GlobeNewswire
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Aug. 24, 2026

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Samoa Wellness Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.